Qrativ, Inc. was founded with the core mission of revolutionizing drug repurposing through innovative healthcare software. The company's vision is to accelerate the discovery and development of new therapeutic uses for existing drugs, thereby improving patient outcomes and reducing the time and cost associated with bringing treatments to market. Qrativ offers a cutting-edge drug purposing platform that leverages advanced data analytics and machine learning to identify potential new applications for existing pharmaceuticals, focusing on unmet medical needs and rare diseases.

Notable affiliated individuals include experts in bioinformatics and pharmaceutical development, contributing to the company's robust scientific foundation. Qrativ has attracted significant investment from leading venture capital firms specializing in healthcare innovation. Key achievements include successful collaborations with major pharmaceutical companies and research institutions, resulting in the identification of promising drug candidates for repurposing. Overall, Qrativ has made a substantial impact on the drug development landscape by streamlining the repurposing process and offering new hope for patients with limited treatment options.